The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.
Michaelis KA, Norgard MA, Zhu X, Levasseur PR, Sivagnanam S, Liudahl SM, Burfeind KG, Olson B, Pelz KR, Angeles Ramos DM, Maurer HC, Olive KP, Coussens LM, Morgan TK, Marks DL.
Michaelis KA, et al. Among authors: olson b.
Nat Commun. 2019 Oct 15;10(1):4682. doi: 10.1038/s41467-019-12657-w.
Nat Commun. 2019.
PMID: 31615993
Free PMC article.